Elan veterans grab $34m for neurodegenerative diseases
This article was originally published in Scrip
Executive Summary
The only two employees at the virtual biotechnology company Annexon Biosciences are former Elan Pharmaceuticals business and research executives Doug Love and Ted Yednock, but they raised $34m in a Series A-1 venture capital funding round to advance drugs for neurodegenerative diseases.
You may also be interested in...
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.